Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial
Exposure to components of fine particulate matter is associated with risk of autism spectrum disorder
Chronic Disease Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial December 22, 2025
Neurology Selective serotonin reuptake inhibitors do not affect cognitive function through breastmilk November 24, 2025
Chronic Disease Exposure to components of fine particulate matter is associated with risk of autism spectrum disorder October 27, 2025
Chronic Disease Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder A Randomized Clinical Trial October 7, 2025
